NCT04637828View on ClinicalTrials.gov

A Study to Compare the Efficacy of GNS561 Versus Standard of Care in Patients With SARS-CoV-2 (COVID-19) Infection

PHASE2UnknownINTERVENTIONAL

Enrollment

178

Participants

Timeline

Start Date

November 18, 2020

Primary Completion Date

July 30, 2021

Study Completion Date

December 30, 2021

Conditions

COVID-19

Interventions

DRUG

GNS561

study drug

Trial Locations (1)

13006

RECRUITING

Genoscience Pharma, Marseille

Sponsors

Lead Sponsor

Genoscience Pharma

All Listed Sponsors

lead

Genoscience Pharma

INDUSTRY

NCT04637828 - A Study to Compare the Efficacy of GNS561 Versus Standard of Care in Patients With SARS-CoV-2 (COVID-19) Infection | Biotech Hunter | Biotech Hunter